Cardiff Oncology Inc
CRDF
NASDAQ
Biotechnology
$0.96
USD
-0.02 (-2.13%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $79.27M
Volume 461.0K
Revenue
$508,000
TTM
-7.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-40.05M
TTM
+21.5%
YoY
Operating Cash Flow
$-40.85M
TTM
+2.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.1 | 0.1 | 0.2 | 0.0 | 0.1 |
YoY Growth | -25.8% | -27.3% | +60.9% | -62.4% | -14.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.1 | 0.1 | 0.2 | 0.0 | 0.1 |
Selling, General & Administrative | 3.3 | 3.9 | 3.0 | 6.1 | 3.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 14.9 | 12.1 | 8.1 | 12.9 | 9.7 |
Operating Income | -14.8 | -12.0 | -7.8 | -12.9 | -9.6 |
EBITDA | -14.7 | -11.9 | -7.7 | -12.8 | -9.5 |
Other Income / Expense | -0.0 | 0.0 | -0.0 | -0.0 | 0.0 |
Total Other Income / Expense | 0.8 | 0.7 | 0.6 | 0.5 | 0.4 |
Income Before Income Taxes | -13.9 | -11.3 | -7.2 | -12.3 | -9.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -13.9 | -11.3 | -7.2 | -12.3 | -9.2 |
Consolidated Net Income / Loss | -13.9 | -11.3 | -7.2 | -12.3 | -9.2 |
Net Income Attributable to Common Shareholders | -13.9 | -11.3 | -7.2 | -12.4 | -9.2 |
Basic EPS | -$0.21 | -$0.17 | -$0.11 | -$0.18 | -$0.14 |
Diluted EPS | -$0.21 | -$0.17 | -$0.11 | -$0.18 | -$0.14 |
Basic Shares Outstanding | 66.5M | 66.9M | 67.4M | 68.4M | 68.4M |
Diluted Shares Outstanding | 66.5M | 66.9M | 67.4M | 68.4M | 68.4M |